Edinburgh Research Explorer

Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia

Citation for published version:

Digital Object Identifier (DOI):
10.1093/emboj/cdg469

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
EMBO Journal

Publisher Rights Statement:
Copyright © 2003 European Molecular Biology Organization

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia

Alfonso Mora1, Anthony M. Davies2, Luc Bertrand3, Isam Sharif4, Grant R. Budas2, Sofija Jovanović2, Véronique Mouton2, C. Ronald Kahn5, John M. Lucocq2, Gillian A. Gray4, Aleksandar Jovanović2 and Dario R. Alessi1

MRC Protein Phosphorylation Unit and 3Division of Cell Biology and Immunology, School of Life Sciences, MSI/WTB Complex, University of Dundee, Dow Street, Dundee DD1 5EH, 2Maternal and Child Health Sciences, Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Dundee, 4Centre for Cardiovascular Science, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, UK, 5Hormone and Metabolic Research Unit, Institute of Cellular Pathology and University of Louvain Medical School, Belgium and 3Joslin Diabetes Centre, Department of Medicine, Harvard Medical School, Boston, MA, USA

1Corresponding author
e-mail: a.m.corral@dundee.ac.uk

We employed Cre/loxP technology to generate mPDK1±/± mice, which lack PDK1 in cardiac muscle. Insulin did not activate PKB and S6K, nor did it stimulate 6-phosphofructo-2-kinase and production of fructose 2,6-bisphosphate, in the hearts of mPDK1±/± mice, consistent with PDK1 mediating these processes. All mPDK1±/± mice died suddenly between 5 and 11 weeks of age. The mPDK1±/± animals had thinner ventricular walls, enlarged atria and right ventricles. Moreover, mPDK1±/± muscle mass was markedly reduced due to a reduction in cardiomyocyte volume rather than cardiomyocyte cell number, and markers of heart failure were elevated. These results suggested mPDK1±/± mice died of heart failure, a conclusion supported by echocardiographic analysis. By employing a single-cell assay we found that cardiomyocytes from mPDK1±/± mice are markedly more sensitive to hypoxia. These results establish that the PDK1 signalling network plays an important role in regulating cardiac viability and preventing heart failure. They also suggest that a deficiency of the PDK1 pathway might contribute to development of cardiac disease in humans.

Keywords: cardiac muscle/heart failure/hypoxia/PDK1/PI 3-kinase/PKB/Akt

Introduction

Hormones and growth factors trigger the activation of members of a group of protein kinases including protein kinase B (PKB) and p70 ribosomal S6k (S6K), which belong to the AGC family of protein kinases (Brazill and Hemmings, 2001; Lawlor and Alessi, 2001; Newton, 2002). The 3-phosphoinositide-dependent protein kinase-1 (PDK1) plays a central role in activating these AGC kinase members by phosphorylating these enzymes at their activation loop (Toker and Newton, 2000; Alessi, 2001). Much research has shown that the PDK1/AGC kinase-signalling pathway regulates diverse cellular processes, such as those relevant to cell survival, proliferation and metabolic responses to insulin. Misregulation of AGC kinase members is thought to contribute to many diseases. For example, hyperactivation of this pathway is implicated in inducing cardiac hypertrophy (Sugden, 2001) and promoting the survival and proliferation of a significant number of cancers (Simpson and Parsons, 2001). A deficiency in the activation of AGC kinases may be a primary cause of the insulin-resistant form of diabetes (Saltiel and Kahn, 2001), as well as neuronal cell death following a stroke (Wick et al., 2002).

The activation of PKB and S6K isoforms by insulin and growth factors, as well as being dependent on PDK1, requires the prior activation of the phosphoinositide 3-kinase (PI 3-kinase) (Vanhaesebroeck et al., 2001). This produces the second messenger, phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3], which binds to the pleckstrin homology domains of PKB and PDK1, recruiting these enzymes to the plasma membrane where PKB is activated by phosphorylation of its activation-loop residue (Thr308 in PKBα) by PDK1 (Brazill and Hemmings, 2001; Scheid and Woodgett, 2001). PtdIns(3,4,5)P3 also stimulates the phosphorylation of PKB at its hydrophobic motif residue (Ser473 in PKBα), which is required for maximal activation of PKB (Alessi et al., 1996; Yang et al., 2002), by an as yet unknown mechanism. In contrast, S6K does not interact with PtdIns(3,4,5)P3 but, instead, PtdIns(3,4,5)P3 stimulates, by a not completely characterized mechanism, the phosphorylation of the hydrophobic motif residue (Thr389 in S6K1) (Avruch et al., 2001; Volarevic and Thomas, 2001). This generates a binding site for PDK1 to interact with, phosphorylate and activate S6K (Biondi et al., 2001, 2002; Frodin et al., 2002; Collins et al., 2003).

The key role that PDK1 plays in activating certain AGC kinase members in mammalian cells was established by the finding that in mouse embryonic stem (ES) cells lacking PDK1, PKB and S6K could not be activated (Williams et al., 2000). Moreover, genetic analysis in Saccharomyces cerevisiae (Casamayor et al., 1999; Inagaki et al., 1999), Saccharomyces pombe (Niederberger and Schweingruber, 1999), Drosophila (Cho et al., 2001c; Rintelen et al., 2001) and Caenorhabditis elegans (Paradis et al., 1999) supports the conclusion that PDK1 is required for the activation of PKB and S6K homologues, as well as being necessary for the viability and development of these model organisms. We have also recently provided evidence that PDK1 is essential for mammalian development, as mice lacking PDK1 die at day E9.5 of embryogenesis due to multiple abnormalities (Lawlor et al., 2002). In this study, to...
learn more about the roles that PDK1 plays after birth/development, we have generated and analysed the cardiac phenotype of mice that lack PDK1 in skeletal and heart muscle.

Results

Generation of mice lacking PDK1 in heart

We previously described (Lawlor et al., 2002) the generation of PDK1fllox/fllox mice in which exons 3 and 4 of the PDK1 gene were flanked with the loxP CRE excision sequence (Figure 1A). These mice, in which PDK1 was expressed in all tissues at the same level as in wild-type mice, were crossed with transgenic mice expressing the CRE recombinase under the muscular creatine kinase promoter which induces expression of this enzyme specifically in skeletal muscle and heart just prior to birth (Bruning et al., 1998). In the resulting PDK1fllox/fllox mice that express the CRE recombinase (termed mPDK1+/+ mice), exons 3 and 4 of the PDK1 would be specifically excised in skeletal and cardiac muscle, thereby ablating functional PDK1 expression, as this truncation prevents translation of the entire kinase and pleckstrin homology domains (Williams et al., 2000). mPDK1+/− mice were born at the expected Mendelian frequency (Figure 1B), and the littermate PDK1fllox/fllox mice not expressing CRE (termed mPDK1+/+) were utilized as the control animals throughout this study.

As expected, the mPDK1+/− mice displayed no significant expression of the PDK1 protein in six different muscles studied, including heart (Figure 1C). In contrast, expression of PDK1 in liver, adipose and brain was identical to the level found in the control mPDK1+/+ mice.

Survival of mPDK1+/− mice

Up to the age of 5 weeks, the mPDK1+/− mice survived normally (Figure 1D), were apparently healthy, displaying no abnormal phenotype, and their growth, as assessed by body weight, was indistinguishable from that of mPDK1+/+ littermates (Supplementary figure 1, available at The EMBO Journal Online). The mPDK1+/− mice breath, eat normally and display the same physical activity as mPDK1+/+ mice. We also measured fasting blood glucose levels in mice up to 8 weeks of age and observed no significant difference between mPDK1+/+ and mPDK1+/− animals (data not shown), indicating that these mice were not markedly diabetic. However, between the ages of 5 and 11 weeks of age, 100% of the mPDK1+/− mice died, whereas the mPDK1+/+ littermates survived as expected (Figure 1D). In all cases, the mice were noticeably less active 2–3 days before they died, and a significant reduction in body weight was observed (Supplementary figure 1). Before this, there were no noticeable differences between mPDK1+/+ and mPDK1+/− mice. There was also no significant difference in the ages at which male and female mice died (data not shown).

Evidence that mPDK1+/− mice develop heart failure

Post-mortem analysis of the mPDK1+/− mice revealed that the hearts of these animals were significantly enlarged, with blood clots found in both atria, which also appeared massively inflated. Morphological analysis of other organs (data not shown) of the mPDK1+/− mice, including skeletal muscle (Supplementary figure 2), presented no evidence of any abnormality. These observations suggested that a lack of PDK1 in cardiac muscle could be inducing heart failure leading to death of the animals. To investigate this in more detail, we performed histological analysis on hearts derived from mPDK1+/− and mPDK1+/+
mice of 2, 4 and 6 weeks of age, as well as on hearts from mPDK1±/± animals after death. This analysis revealed that the mPDK1±/± hearts were slightly smaller at 2 weeks of age (Figure 2A), the thickness of the ventricular walls was normal and the atria of normal size (Figure 2B). Moreover, analysis of cardiac tissue of 2-week-old mice, revealed no evident abnormalities or significant differences in cardiomyocyte size (Figure 2C). By 4 weeks of age, the difference in size between the mPDK1±/± and mPDK1+/+ hearts was more obvious (Figure 2D), but no major abnormality was noticeable in the ventricular walls (Figure 2E) or cardiac tissue (Figure 2F). By 6 weeks of age, however, the mPDK1±/± hearts were markedly smaller (Figure 2G), the ventricle walls were significantly thinner (Figures 2H and 3A) and the atria enlarged compared with control mPDK1+/+ heart (Figure 2H). Strikingly, the right ventricle was significantly enlarged in mPDK1±/± hearts, while the overall size of the left ventricle was similar but the muscle walls were much thinner (Figures 2H and 3A). Additionally, in the cardiac tissue, the cardiomyocytes appeared more separated from each other and possibly slightly smaller (Figure 2I). After death, the mPDK1±/± hearts were enlarged and appeared bigger than control mPDK1+/+ hearts (Figure 2J). Moreover, at this stage, the ventricular walls of the mPDK1±/± hearts were vastly thinner (Figure 2K). Post-mortem analysis of mPDK1±/± hearts confirmed that cardiac tissue had significantly expanded, resulting in marked separation of myocytes (Figure 2L). We were unable to detect myocyte disarray in mPDK1±/± hearts at any age, including after death (Supplementary figure 3).

**In vivo echocardiographic analysis in mPDK1±/± mice**

Echocardiographic analysis of 5- to 6-week-old mPDK1±/± mice revealed the development of heart failure, reflected in a reduction in both fractional shortening and ejection fraction (Figure 3B). Thinning of the left ventricle was also confirmed by a significant reduction in the posterior wall thickness measured during diastole (Figure 3B). At this stage, there was no evidence for an increase in left ventricular dimension, although an enlarged right ventricle was visible in some of the echocardiographic images.

**Quantitative analysis of muscle mass, cardiomyocyte volume and number**

In order to further characterize the cardiac phenotype of mPDK1±/± mice, we employed rigorous unbiased methods for determining total muscle mass, average cardiomyocyte volume and total cardiomyocyte number. The muscle mass was calculated using the Cavalieri method, whereas the cardiomyocyte volume and cardiomyocyte number in
the heart tissue were determined using a stereological approach called the dissector principle (Sterio, 1984; Gunderson, 1986). The muscle mass of mPDK1±/± hearts was significantly reduced and the difference in muscle mass between mPDK1±/± and mPDK1+/+ hearts increased with age (Figure 4A). The number of cardiomyocytes in the mPDK1±/± and mPDK1+/+ hearts was similar at all ages (Figure 4B). The average estimated volume of mPDK1±/± cardiomyocytes was significantly lower and the difference in volume between mPDK1±/± and mPDK1+/+ myocytes increased with age (Figure 4C). These findings show that a reduced cardiomyocyte volume rather than a decrease in cell number caused the reduction in muscle mass of the mPDK1±/± hearts.

Interestingly, histological analysis of the quadriceps of skeletal muscle of 6-weeks-old mPDK1±/± and mPDK1+/+ mice revealed no significant reduction in muscle fibre diameter (Supplementary figure 2). As muscle fibres are formed from fused cells, it is difficult to assess whether the fibres are formed from a larger number of smaller cells or whether limb skeletal muscle cells lacking PDK1 are not reduced in cell size.

Further evidence of cardiomyopathy in mPDK1±/± mice

Disease progression in cardiomyopathy in humans can result primarily from myocardial injury and hypertension, as well as genetic factors, causing a marked increase in cardiac chamber volume and separation of cardiomyocytes. This leads to the accumulation of collagen in the intracellular space (Crackower et al., 2002b). We therefore measured the collagen content of the mPDK1±/± and mPDK1+/+ hearts using the quantitative Cavalieri method and a collagen specific stain. At weeks 2 and 4, mPDK1±/± and mPDK1+/+ hearts contained similar levels of collagen (Figure 5A). However, by 6 weeks of age and after death, the collagen content in the mPDK1±/± hearts was markedly elevated compared with control mPDK1+/+ hearts. Another key feature of heart failure is the reactivation of an embryonic gene programme (Hunter and Chien, 1999). The mRNA levels of both the atrial natriuretic factor and β-myosin heavy chain, two embryonic genes used as molecular markers of heart failure (Crackower et al.,...
were found to be significantly increased in the hearts derived from 6-week-old mPDK1 <sup>+/−</sup> mice (Figure 5B). The p38 mitogen activated protein kinase has been reported to play a role in regulating myocardial cell growth. p38 is partially activated in normal hearts and is further stimulated by diverse hypertrophic insults (Behr et al., 2001). Moreover, it has also been reported that p38 is inactivated in failing human heart (Communal et al., 2002). We therefore assessed p38 activity using a phosphospecific antibody and found that in 6-week-old mPDK1 <sup>+/−</sup> hearts, p38 phosphorylation was markedly reduced compared with control mPDK1 <sup>+/+</sup> hearts (Figure 5C, upper panel), consistent with the notion that p38 activity might be down regulated in the failing heart. The phosphorylation of other MAP kinase members, ERK1/ERK2 (Figure 5C, lower panel) and JNK1/JNK2 (data not shown) was similar in 6-week-old mPDK1 <sup>+/−</sup> and mPDK1 <sup>+/+</sup> hearts. A characteristic feature of cardiomyopathy, termed dilated cardiomyopathy, is an increase in the...
Z-line thickness in sarcomeres resulting from over-stretching of cardiac muscle (Knoll et al., 2002). We therefore measured Z-line thickness, using electron microscopy, of mPDK1±/± mice, normal-weight mice (~6 weeks old) and mice that had started to lose weight (~8 weeks old) and were predicted to die soon. This analysis revealed that at 6 weeks of age there was no significant difference in Z-line thickness but by 8 weeks of age the Z-line was found to be significantly thicker in the mPDK1±/± mice (Figure 5D). The structure, length and organization of the mPDK1±/± and mPDK1+/+ sacromeres was found to be similar in mice of up to 6 weeks of age.

Fig. 6. Activation of PKB, S6K and PFK2 in heart by insulin. Mice were fasted overnight and injected with either saline for 10–20 min (for the 0 time point control) or 1 mU/g of insulin for the indicated times. The heart was then rapidly extracted and frozen in liquid nitrogen. PKB (A) or S6K (B) were immunoprecipitated from cardiac extract and the activity determined using a quantitative peptide phosphorylation assay. Each point represents the mean activity ± SD of three different hearts with each assayed in triplicate. (C and D) As above except that cell lysates form the indicated hearts were immunoblotted with the indicated antibodies. Each lane represents a different mouse PFK-2 activity (E) and fructose-2,6-bisphosphate (Fru-2,6-P2) levels (F) were measured as described in the Materials and methods. Each point represents the mean activity ± SD of three to five different hearts with each assayed in duplicate.

Analysis of PKB and S6K activation in mPDK1+/+ and mPDK1±/± hearts
To determine whether lack of expression of PDK1 in heart impaired activation of characterized PDK1 substrates, mPDK1+/+ and control mPDK1±/± mice were injected with insulin for varying times and heart extracts generated. Activity of PKB (Figure 6A) and S6K (Figure 6B) was
measured by a quantitative immunoprecipitation kinase assay. In hearts derived from mPDK1+/− mice, insulin induced a 10-fold activation of PKB within 5 min and a 6-fold activation of S6K within 20 min. The low basal activity of PKB and S6K in unstimulated mPDK1+/− hearts was similar to that observed in mPDK1+/+ mice, but was not further activated by insulin.

In Figure 6C, the activation of PKB was also assessed using phoshspecific antibodies raised against the site of PDK1 phosphorylation (Thr308) as well as the hydrophobic motif phosphorylation site (Ser473), which is thought to be phosphorylated independently of PDK1. Insulin induced Thr308 phosphorylation of PKB in mPDK1+/+ hearts within 2 min, but as expected, no phosphorylation of Thr308 was detected in insulin-treated mPDK1−/− hearts at any time point tested. In unstimulated mPDK1+/+ hearts, PKB is not phosphorylated at Ser473 and insulin induced a marked phosphorylation of this residue (Figure 6C). In contrast, in unstimulated mPDK1−/− hearts, PKB was markedly phosphorylated at Ser473, to a level similar to that observed in insulin-stimulated mPDK1+/+ hearts. Stimulation of mPDK1−/− mice with insulin only induced a small additional increase in phosphorylation of PKB at Ser473. Similar findings have been made in mouse ES cells lacking PDK1 (Williams et al., 2000) and suggest that there may be some cross-talk between the regulation of the as yet uncharacterized PKB Ser473 kinase and PDK1.

The hydrophobic motif phosphorylation site on S6K (Thr389) plays a key role in regulating the activation of this kinase (Pearson et al., 1995). Recent work by several groups suggested that phosphorylation of Thr389 is regulated by PKB-catalysed phosphorylation of the tuberin tumour suppressor protein, and also involves mTOR (reviewed in McManus and Alessi, 2002). Consistent with this notion and the lack of PKB activity in mPDK1−/− hearts, insulin failed to stimulate S6K phosphorylation at Thr389 in mPDK1−/− hearts (Figure 6D). In contrast, in mPDK1+/+ hearts, insulin stimulated a marked phosphorylation of Thr389 within 10–20 min. Moreover, insulin also induced the phosphorylation of the PKB substrates GSK3α and GSK3β (Figure 6C) and the S6K substrate ribosomal S6 protein (Figure 6D), in mPDK1+/+ hearts but not in mPDK1−/− hearts.

**Genetic evidence that PDK1 mediates insulin activation of 6-phosphofructo-2-kinase**

The heart adapts its energy consumption to the availability of substrates and hormones. Under normal conditions, fatty acids are preferred to glucose. Hormones like insulin modify this hierarchy. Insulin inhibits fatty acid oxidation and stimulates glucose consumption (Hue et al., 2002). Stimulation of heart glycolysis by insulin is thought to be mediated through glucose transporter translocation and activation of 6-phosphofructo-2-kinase (PFK-2), which generates fructose 2,6-bisphosphate, the allosteric activator of 6-phosphofructo-1-kinase, a key enzyme of glycolysis (Deprez et al., 1997; Hue et al., 2002). PFK-2 is activated in vivo by phosphorylation of Ser466 and Ser483 lying in an AGC kinase phosphorylation motif (Bertrand et al., 1999). In vitro Ser466 and Ser483 are phosphorylated by several AGC kinases including PKB (Deprez et al., 1997). In vivo phosphorylation of these sites is induced by insulin and this phosphorylation is prevented by treatment of cells with PI 3-kinase inhibitors, but it is not yet clear whether PKB or another insulin-stimulated wortmannin-sensitive kinase mediates this phosphorylation in vivo (Deprez et al., 2000). In order to assess the role of PDK1 in regulating activation of PFK-2, mPDK1+/+ and mPDK1−/− mice were injected with insulin and at varying times hearts extracted and PFK-2 activity (Figure 6E) and fructose 2,6-bisphosphate levels (Figure 6F) measured. In mPDK1+/+ mice, PFK-2 activity was stimulated nearly 2-fold within 5 min of insulin injection and accumulation of fructose 2,6-bisphosphate was detected after 10 min, reaching ~5-fold higher levels than in unstimulated mPDK1+/+ hearts after 20 min. In the mPDK1−/− hearts, no significant increase in PFK-2 activity or fructose 2,6-bisphosphate levels was detected after insulin injection.

**Evidence that mPDK1−/− cardiomyocytes are more sensitive to hypoxia**

Metabolic stresses such as hypoxia leading to myocardial injury are one of the known causes of heart failure (Hirota et al., 1999; Cesselli et al., 2001). We therefore decided to test whether PDK1−/− cardiomyocytes are more sensitive to hypoxia compared with control animals. Cardiomyocytes were isolated from mPDK1−/− and mPDK1+/+ hearts of 4-week-old mice, when significant heart disease had not yet developed (Figures 2–5). The isolated mPDK1−/− cardiomyocytes were 40% smaller as estimated by laser confocal microscopy (Supplementary figure 4), similar to the reduction observed for cardiomyocytes in cardiac tissue (Figure 4C). Parameters of cell viability of mPDK1−/− cardiomyocytes including membrane potential (Figure 7A), resting intracellular calcium concentration ([Ca2+]i) (Figure 7B) and diameter ratio (Figure 7C) were similar to those observed for mPDK1+/+ cardiomyocytes. Isolated mPDK1−/− and mPDK1+/+ field-stimulated beating cardiomyocytes were subjected to hypoxic conditions and monitored continuously for [Ca2+]i and cell morphology (Figure 7D–F). In mPDK1+/+ cardiomyocytes, hypoxia induced intracellular Ca2+ overload associated with an irreversible cell collapse of the rod-shape structure (hypercontracture, leading to decrease in diameter ratio; indicative of cell death) (Jovanović et al., 1998) after ~35 min (Figure 7D–F). The beating mPDK1−/− cardiomyocytes were markedly more sensitive to hypoxia than mPDK1+/+ cardiomyocytes, surviving for an average of only ~15 min (Figure 7D–G). Hypoxia did not induce intracellular Ca2+ loading or cellular hypercontracture when extracellular Ca2+ was removed from the extracellular medium (Figure 7H) or intracellular Ca2+ stores were blocked with thapsigargin plus ryanodine (Figure 7I). We also performed measurements of Ca2+ transients in mPDK1+/− and mPDK1+/+ mice in field-stimulated cardiomyocytes using laser confocal microscopy and Fluoro-3 Ca2+-sensitive dye, and no differences in properties of Ca2+ transients or cell shortening between different cell types were observed (data not shown), suggesting that PDK1 may not act as a negative regulator of cardiac contractility.

To analyse whether the increased sensitivity of mPDK1−/− cardiomyocytes to hypoxia was due to
apoptosis, we set up a whole-heart assay in which mPDK1±/± and mPDK1+/+ hearts were cannulated and perfused under normoxic or hypoxic conditions for 4 h. The activity of caspase 3, and cleavage of caspase 3, caspase 7 and PARP protein, general markers for apoptosis, were found to be similar in normoxic and
hypoic mPDK1−/− and mPDK1+/− hearts (Supplementary figure 5), indicating that the mPDK1−/− hearts were not failing due to an increase in apoptosis. As a control, mPDK1+/− hearts were treated with the apoptosis-inducing non-specific kinase inhibitor staurosporine, which markedly increased caspase-3 activity and the cleavage of caspase 3, caspase 7 and PARP (Supplementary figure 5).

Discussion

In this study, we provide the first genetic evidence that PDK1 plays multiple roles in regulating cardiac viability. Our analysis indicates that mPDK1−/− mice die suddenly at an early stage of adult life, possess the same number of smaller cardiomyocytes and develop heart failure, and that cardiomyocytes lacking PDK1 are significantly more sensitive to hypoxia.

Mice models have previously been used to explore the role of the PI 3-kinase pathway in heart. Mimicking the activation of the PI 3-kinase pathway by overexpression of active forms of PI 3-kinase-α (Shioi et al., 2000), knockout of PTEN (Crackower et al., 2002a) and overexpression of active PKB (Condorelli et al., 2002; Shioi et al., 2002), resulted in an increase in the size of the heart (hypertrophy) due to increased cell size. Conversely, knockout of the insulin receptor (Belke et al., 2002) or the overexpression of dominant-negative PI 3-kinase (Shioi et al., 2000), decreased heart size (hypotrophy) by reducing cardiomyocyte volume. A number of studies have established that in both Drosophila and mice the PI 3-kinase/PDK1/AGC kinase pathway plays an important role in regulating cell size in all tissues investigated (reviewed in Kozma and Thomas, 2002). Consistent with this notion, we have also shown that mouse embryonic endoderm cells lacking PDK1 have a 60% reduced cytoplasmic volume (Lawlor et al., 2002). Moreover, PDK1 hypomorphic mice that express only 10% of the normal level of PDK1 are ~40% smaller, and our analysis indicated this was due to these animals possessing smaller cells (Lawlor et al., 2002). In agreement with the notion that PDK1 plays a major role in regulating cell volume, we show that mPDK1−/− hearts are smaller, as a consequence of decreased cardiomyocyte size (Figures 2 and 4; Supplementary figure 4). At present, it is not possible to conclude whether it is the lack of activation of PKB, S6K or another PDK1 substrate that mediates the reduction in cardiomyocyte volume in mPDK1+/− mice. The knockouts thus far described for PKBα (Chen et al., 2001b; Cho et al., 2001b), PKBβ (Cho et al., 2001a) and S6K1 (Shima et al., 1998) were not reported to reduced heart size or cardiac phenotype, but this could be due to the presence of other isoforms of these kinases. PKB was assessed to play a central role in regulating cardiac size based on the results obtained with mice overexpressing 10- to 30-fold higher PKB levels than found physiologically (Condorelli et al., 2002; Shioi et al., 2002). However, it should be pointed out that a decrease in cell size in the PDK1 hypomorphic mice occurred under conditions where insulin was able to trigger normal activation of PKB and S6K (Lawlor et al., 2002), suggesting that PDK1 may regulate cell size independently of PKB and S6K.

In contrast to other genetic models of the PI 3-kinase pathway generated thus far, the mPDK1+/− mice are the only ones that develop cardiomyopathy leading to death in early adulthood. One of the reasons for this could be that the smaller mPDK1−/− hearts are not able to properly fulfill necessary cardiac function in adult mice. The mPDK1−/− mice fulfil the main criteria to support the diagnosis of heart failure. This includes marked thinning of ventricular walls assessed by both histological and echocardiographic analysis, contractile dysfunction assessed by echocardiography, separation of cardiomyocytes within cardiac tissue, increased collagen content, abnormal expression of embryonic genes and an increase in Z-line thickness prior to death. The findings that the myofibrils are not disorganized in the mPDK1−/− mice (Supplementary figure 3), that the ventricle walls are thinner (Figures 2 and 3) and that p38 activation in hearts of mPDK1−/− mice is reduced (Fig 5C) argues against hypertrophy. Previously, cardiac hypotrophy was observed in mice lacking the insulin receptor (Belke et al., 2002) or overexpressing dominant-negative PI 3-kinase (Shioi et al., 2000), but the mice did not develop heart failure. The main difference between these models and the mPDK1−/− mice is that the activity of PKB, S6K and probably other PDK1-regulated AGC kinase substrates are totally ablated in mPDK1−/− hearts. PDK1 hypomorphic mice possess markedly hypotrophic hearts (A.Mora and A.Jovanovic, unpublished data), but did not develop heart failure (Lawlor et al., 2002). A key role for the PKB pathway is to suppress apoptosis, and therefore the development of heart failure in mPDK1−/− mice could have resulted from increased apoptotic cell death. Our data would argue against this, as the number of cardiomyocytes in mPDK1+/+ and mPDK1−/− hearts is similar (Figure 4B), and by the finding that markers of apoptosis (caspase 3, cleavage of caspase 3,caspase 7 and PARP) are not elevated in mPDK1−/− hearts (Supplementary figure 5).

In humans, one of the major causes of heart failure is ischaemic heart disease associated with hypoxia (Hirota et al., 1999; Cesselli et al., 2001). Work carried out over the last 15 years has demonstrated that ischaemia/hypoxia activates signalling pathways that enable cardiomyocytes to survive under these adverse conditions (Sugden and Clerk, 1998; Marber, 2000). Previous studies employing inhibitors of PI 3-kinase and overexpression of constitutively active or dominant-negative mutants of PI 3-kinase and PKB, in general, support the conclusion that this pathway plays a role in promoting survival in hypoxic and other stressful conditions (Fujio et al., 2000; Chen et al., 2001a; Jonassen et al., 2001; Baines et al., 2002). In the present study, we have used field-stimulated beating cardiomyocytes to directly measure the effect that lack of PDK1 has on resistance to hypoxia. We employed this approach as single cardiomyocytes are free of hormonal, neuronal and vascular influences, and thus any difference between control and mPDK1−/− myocytes can be ascribed reliably to the absence of PDK1. Bearing in mind that the initial metabolic condition of a cardiomyocyte may determine the outcome of a stress (Jovanovic et al., 1996), it is important to note that mPDK1−/− and mPDK1+/− cardiomyocytes had similar parameters of cell viability at rest (Figure 7A–C). We found that mPDK1−/− cardiomyocytes were considerably more sensitive to hypoxia than control mPDK1+/− cardiomyocytes (Figure 7). In previous studies, it has been shown that
‘chemical’ hypoxia induces necrotic cell death by increasing intracellular Ca²⁺ via mechanisms that involve both extracellular and intracellular Ca²⁺ pools (Jovanović and Jovanović, 2001). In addition to these studies, we now provide evidence that extracellular Ca²⁺ as well as Ca²⁺ stored in subcellular compartments contribute to Ca²⁺ overload under ‘genuine’ hypoxia. We show that removal of extracellular Ca²⁺ throughout hypoxia can abolish Ca²⁺ loading as well as treatment with agents that deplete or inhibit intracellular Ca²⁺ stores (Figure 7H and I). Thus, Ca²⁺ loading following hypoxia of cardiomyocytes may have occurred through influx and release of Ca²⁺ from intracellular stores. Whole-heart experiments suggest a necrotic nature of hypoxia-induced cell death rather than apoptotic (Supplementary figure 5).

Although we have provided evidence for a role of PDK1 in promoting cardiomyocyte survival and preventing heart failure, it should be noted that further research is required to establish whether the increased sensitivity of mPDK1−/− cardiomyocytes to metabolic stresses (Figure 7) contributes to the development of heart failure in mPDK1−/− mice. Moreover, we have shown that in mPDK1−/− hearts, PFK-2 cannot be activated by insulin (Figure 6E and F), which would prevent the stimulation of glycolysis by insulin. The loss of the stimulation of glycolysis by insulin could modify the regulation of the fuel hierarchy by this hormone and such disruption could contribute to onset of heart failure in mPDK1−/− mice. It has to be noted that insulin, in combination with glucose and potassium, exerts a protective effect on the ischaemic heart by reducing infarct size and improving post-ischaemic left ventricular function. Even if the exact role of insulin remains unclear, the cardiac protection conferred by the hormone appears when the coronary flow is restored and may be related to the metabolic effect favouring glucose utilization instead of fatty acid oxidation (Beauloye et al., 2001; Hue et al., 2002). The loss of this beneficial effect of insulin could also contribute to the heart phenotype of mPDK1−/− mice.

In conclusion, we have provided firm genetic evidence that PDK1 regulates heart growth and viability. Moreover, we also show that PDK1 is necessary for the activation of PFK-2 and production of fructose 2,6-bisphosphate induced by insulin, and provide evidence that PDK1 is implicated in cardioprotective signalling. Taken together, the data presented in this study suggest that cardiomyopathies resulting in ventricular thinning and dilatation and ischaemic heart disease in humans could perhaps be treated by strategies that trigger the activity of PDK1.

Materials and methods

Materials and methods are presented as Supplementary data available at The EMBO Journal Online.

Acknowledgements

We thank Vicky Murray-Tait for help importing and rederiving the MckCre mice, Luke Newman and Sandy Harper for help in organizing mouse studies, Margaret Lawlor for discussion, Jane Leitch and Moustapha Aoubala for preparation of antibodies and Calum Thomson for technical help in the cell size studies. The work was supported by BBSRC (A.J.), British Heart Foundation (A.J., D.R.A. and G.A.G.), Tenvorus-Scotland (A.J.), the Wellcome Trust (A.J. and J.M.L.-059767/Z/99/Z), the ‘Actions de Recherche Concertées’ 98/03-216 from the French Community of Belgium (L.B.), Belgian F.R.I.A. (V.M.), the Belgian Fund for Medical Research and the Belgian Federal Government (IAF 5). A.M. was supported by a postdoctoral fellowship from the Spanish government. D.R.A. also acknowledges the support of the pharmaceutical companies backing the Division of Signal Transduction Therapy unit in Dundee (AstroZenea, Boehringer Ingelheim, GlaxoSmithKline, Novo-Nordisk and Pfizer).

References


Received February 14, 2003; revised July 10, 2003; accepted July 28, 2003

A. Mora et al.